Project Grant R21CA303648
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $401K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This Project Grant award, provided by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" program (CFDA 93.286), supports research to develop a novel imaging method called "Hydralazine-Augmented Contrast Ultrasound (HYCUS)" for early-stage detection of hepatocellular carcinoma (HCC). The $499,909 award, granted on August 11, 2025, will be used by the University...
- The National Cancer Institute (NCI) awarded Imcare Biotech, Inc. a $364,763 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate SERAVUE AI, a novel multi-analyte algorithmic assay for early detection of hepatocellular carcinoma (HCC), the most common type of primary liver cancer. The project aims to create a highly accurate, non-invasive blood test for HCC surveillance that could potentially replace ultrasound as the standard screening...
- The federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $400,000.00 in funding to Zeest Bio Inc. to develop a novel liver-specific positron emission tomography (PET) tracer. The project aims to complete the preclinical testing and Investigational New Drug (IND)-enabling studies required for first-in-human clinical trials of this PET tracer. This tracer is hypothesized to offer higher sensitivity for detecting smaller...
- This Project Grant award of $306,739.00, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), aims to improve treatment outcomes for patients with hepatocellular carcinoma (HCC), the most prevalent form of liver cancer. The research focuses on identifying the most effective inhibitors of the enzyme ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) in HCC models. ENPP1 plays a key role in suppressing the immune response against HCC...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $275,092 to the University of Wisconsin System to develop an accurate and robust targeting technique to enable transcostal histotripsy treatment of liver tumors. The project aims to improve histotripsy treatments for liver cancer by quantifying the effect of intervening ribs on targeting accuracy and developing a machine learning-based solution to overcome acoustic aberrations from the...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will support research at the University of Texas MD Anderson Cancer Center to develop mathematical models and computational tools for optimizing the delivery of a transarterial ablative therapy for treating hepatocellular carcinoma (liver cancer). The $536,836 award will fund a multi-disciplinary research effort to formulate mathematical models that capture the complex physical and...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded Loyola University of Chicago a $461,844 project grant titled "Hyperpolarized 13C Metabolic Imaging of Tumorigenesis in the Liver". The objective is to use novel hyperpolarized 13C probes to image glycolysis, a critical pathway in hepatocellular carcinoma (HCC) development, and establish in vivo imaging biomarkers to assess altered liver metabolism during HCC progression. The project aims to synthesize a...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) totaling $2,876,456 will support the development of a strategy for hepatocellular carcinoma (HCC) risk assessment in cirrhosis and non-cirrhosis patients with major viral and metabolic etiologies, as well as resources for cholangiocarcinoma (CCA) risk biomarkers. The grant will be used by the University of Texas Southwestern Medical Center to build upon their previously developed...
- This Project Grant award for $468,139, provided by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research at Tulane University to investigate the role of the long non-coding RNA CRNDE in suppressing the immune response to hepatocellular carcinoma. The project aims to elucidate the molecular mechanisms by which CRNDE inhibits tumor-infiltrating lymphocytes, and to evaluate the in vivo anti-cancer efficacy of CRNDE inhibition in mouse models. The...
- This $161,400 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research by the Mayo Clinic to evaluate the therapeutic benefits of ferroptosis, a novel form of cell death, for treating cholangiocarcinoma (CCA), a highly lethal liver and bile duct cancer. The research aims to elucidate how CCA cells, including those resistant to conventional therapies due to genetic mutations, can be targeted through the induction of...